Is the circulating plasma volume sufficiently maintained? Fluid management of an aneurysmal subarachnoid hemorrhage in the acute phase
- PMID: 22989722
- DOI: 10.1179/1743132812Y.0000000093
Is the circulating plasma volume sufficiently maintained? Fluid management of an aneurysmal subarachnoid hemorrhage in the acute phase
Abstract
Cerebral vasospasm is a well-known cause of mortality and morbidity following aneurysmal subarachnoid hemorrhage (SAH). Prevention of symptomatic cerebral vasospasm is the basic management after SAH. Numerous pharmaceutical therapies and endovascular treatments are available against cerebral vasospasm, but none of them have so far proven to improve the outcome. We have focused on maintaining the circulation volume in order to prevent cerebral vasospasm. But to maintain the central venous pressure, huge infusion volume was required, and hyponatremia was frequently observed due to natriuresis and osmotic diuresis. Excessive natriuresis and diuresis cannot be managed through sodium and water replacement, since sodium replacement induces further natriuresis and diuresis (desalination), and water replacement induces hyponatremia. We therefore administered fludrocortisone and hydrocortisone to inhibit excessive natriuresis and diuresis. The efficacy of sodium reabsorption therapy is extremely high to maintain the circulation volume that might have a therapeutic effect to prevent cerebral vasospasm. In this article, we review our institution's experience regarding the management of patients with aneurysmal SAH and also discuss the importance of water and sodium balance when managing such patients.
Similar articles
-
Early inhibition of natriuresis suppresses symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.Cerebrovasc Dis. 2013;35(2):131-7. doi: 10.1159/000346586. Epub 2013 Feb 7. Cerebrovasc Dis. 2013. PMID: 23406891
-
Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage.J Neurosurg. 1999 Dec;91(6):947-52. doi: 10.3171/jns.1999.91.6.0947. J Neurosurg. 1999. PMID: 10584839 Clinical Trial.
-
Prophylactic management of excessive natriuresis with hydrocortisone for efficient hypervolemic therapy after subarachnoid hemorrhage.Stroke. 2003 Dec;34(12):2807-11. doi: 10.1161/01.STR.0000103744.05430.99. Epub 2003 Dec 1. Stroke. 2003. PMID: 14657545 Clinical Trial.
-
Corticosteroids in the Management of Hyponatremia, Hypovolemia, and Vasospasm in Subarachnoid Hemorrhage: A Meta-Analysis.Cerebrovasc Dis. 2016;42(3-4):263-71. doi: 10.1159/000446251. Epub 2016 May 14. Cerebrovasc Dis. 2016. PMID: 27173669 Review.
-
"Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage.Neurocrit Care. 2006;4(1):68-76. doi: 10.1385/NCC:4:1:068. Neurocrit Care. 2006. PMID: 16498198 Review.
Cited by
-
Guidelines for the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage.Neurocrit Care. 2023 Aug;39(1):1-28. doi: 10.1007/s12028-023-01713-5. Epub 2023 May 18. Neurocrit Care. 2023. PMID: 37202712
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources